ReviewHuman vaccines & immunotherapeutics2026
Development of mRNA vaccines against herpes zoster.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ), caused by varicella-zoster virus (VZV), remains a substantial public health burden, particularly in aging populations, due to the risk of severe complications like postherpetic neuralgia (PHN). While existing vaccines (eg. Shingrix®) have advanced prevention efficiencies, they present notable limitations, such as high reactogenicity and complex manufacturing. mRNA vaccines represent a transformative alternative with rapid manufacturing, precise antigen design, and favorable safety. This review synthesizes the current landscape of mRNA vaccine development for HZ, focusing on the rational design of antigen constructs, innovations in lipid nanoparticle delivery systems, insights from preclinical immunogenicity studies, and the progress of leading candidates into clinical trials. In summary, this review highlights the potential of mRNA vaccines to address the limitations of current options, potentially offering a new paradigm for safer, highly efficacious, and scalable HZ prevention. Continued clinical validation is crucial to realize this potential and alleviate the global disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.